Medpace Holdings, Inc. reported second-quarter 2026 results with revenue of $707.33M, net income of $121.36M and diluted EPS of $4.25, versus $603.31M, $90.26M and $3.1, respectively, in the year-ago quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$707.33M$603.31M17.2% | Net income²$121.36M$90.26M34.5% | Diluted EPS³$4.25$3.137.1% |
¹ Reported as “Revenue, net (includes $ 4.7 million and $ 16.9 million with related parties for the three months ended June 30, 2026 and 2025, respectively, and $ 12.0 million and $ 30.7 million with related parties for the six months ended June 30, 2026 and 2025, respectively)”. ² Reported as “Net income”. ³ Reported as “Diluted income per share attributable to common shareholders”.
Business Highlights
- Revenue growth was driven by strength in Oncology, Metabolic, CNS and AVAI services, contributing to a 17.2% increase in the quarter and 21.7% year-to-date growth.
- Most contracts are fixed-fee or unit-of-service; higher reimbursable out-of-pocket costs increased cost volatility during the period.
- Medpace operates a global platform of roughly 6,500 employees across 46 countries, providing broad patient and regulatory access.
- Backlog stood at $3.01B, with approximately $1.95–1.97B expected to convert to revenue within the next 12 months.
- Strong operating cash flow is funding capital investment, infrastructure and selective bolt-on acquisitions.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.